ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
That panitumumab in combination with Epirubicin, Cisplatin and Capecitabine (ECX) will safely
decrease the frequency of pT3/T4 below that of ECX alone in subjects with locally advanced
adenocarcinoma of the stomach and gastroesophageal junction.